» Articles » PMID: 18407769

The Recombinant Humanized Anti-IL-6 Receptor Antibody Tocilizumab, an Innovative Drug for the Treatment of Rheumatoid Arthritis

Overview
Specialties Biology
Pharmacology
Date 2008 Apr 15
PMID 18407769
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: IL-6 is a pro-inflammatory cytokine with multiple roles in the pathogenesis of rheumatoid arthritis (RA). Targeting IL-6 with the humanized anti IL-6 receptor antibody tocilizumab was effective in several placebo-controlled clinical studies in RA.

Objectives: To address how clinically efficacious blockade of IL-6 signalling with inteleukin-6 receptor antibody is in RA patients and what the potential mode of action explaining tocilizumab activity in RA treatment could be.

Results/conclusion: IL-6 induces autoantibody-producing plasma cells and effector T cells and is implicated in the development of clinical signs and symptoms, including increased synthesis of acute phase reactants, fatigue, anaemia and anorexia. Its effects also included significant improvements in American College of Rheumatology (ACR)20, ACR50 and ACR70 values, as well as in health-related quality of life measures, compared with controls. Tocilizumab also prevents radiographic progression of joint damage. Tocilizumab is generally well tolerated and efficacious in patients refractive to conventional DMARD therapies.

Citing Articles

Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study.

Leng X, Tang X, Hu P, Guan X, Li Q, Huang C Front Immunol. 2023; 13:1110992.

PMID: 36926529 PMC: 10011485. DOI: 10.3389/fimmu.2022.1110992.


Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.

Gao Q, Yin X, Tan B, Wang J, Chen J, Zhao B BMC Infect Dis. 2022; 22(1):929.

PMID: 36503381 PMC: 9742033. DOI: 10.1186/s12879-022-07896-0.


Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.

Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D Cells. 2022; 11(21).

PMID: 36359761 PMC: 9655436. DOI: 10.3390/cells11213362.


Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS.

Terzi F, Demirci B, Cinar I, Alhilal M, Erol H Respir Res. 2022; 23(1):249.

PMID: 36115998 PMC: 9482261. DOI: 10.1186/s12931-022-02172-w.


Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.

Malek R, Bill C, Vines C Biomed Pharmacother. 2021; 144:112276.

PMID: 34624681 PMC: 8486678. DOI: 10.1016/j.biopha.2021.112276.